BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001) is a phase 1/2 interventional study registered as NCT07193511 by Avenzo Therapeutics, Inc., with 355 participants planned, started 2025-10-02 and due to reach its primary completion in 2030-03. Interventions recorded: AVZO-103 and Combination Agent.